Activation of the ErbB2/ErbB3 signaling unit via overexpression of the receptors, gain-of-function oncogenic mutations, or autocrine release of the ErbB3 ligand, heregulin, have been identified in many types of cancer (Holbro et al., 2003; Wolf-Yadlin et al., 2006; Sheng et al., 2010; Jaiswal et al., 2013; Capparelli et al., 2015). This evidence concerns the gene ERBB2 and cancer.